Polar Asset Management Partners Inc. Has $23.95 Million Holdings in Glaukos Co. (NYSE:GKOS)

Polar Asset Management Partners Inc. cut its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 26.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 159,710 shares of the medical instruments supplier's stock after selling 58,190 shares during the period. Polar Asset Management Partners Inc. owned approximately 0.29% of Glaukos worth $23,947,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in GKOS. IFP Advisors Inc acquired a new position in shares of Glaukos in the 4th quarter valued at $43,000. Asset Planning Inc purchased a new position in shares of Glaukos in the fourth quarter worth approximately $90,000. CoreCap Advisors LLC raised its holdings in shares of Glaukos by 36.4% during the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock valued at $112,000 after acquiring an additional 200 shares during the period. Picton Mahoney Asset Management purchased a new stake in shares of Glaukos in the 4th quarter valued at approximately $125,000. Finally, SBI Securities Co. Ltd. acquired a new position in Glaukos in the 4th quarter worth approximately $153,000. 99.04% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares of the company's stock, valued at $5,708,568.04. This represents a 2.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.40% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on GKOS shares. Wells Fargo & Company downgraded shares of Glaukos from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $160.00 to $86.00 in a research note on Thursday, May 1st. Piper Sandler lowered their price target on Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a report on Tuesday, April 15th. Stifel Nicolaus dropped their price target on Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Needham & Company LLC decreased their price objective on Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Finally, Truist Financial reaffirmed a "buy" rating and set a $135.00 target price (down previously from $140.00) on shares of Glaukos in a research note on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $134.67.

Glaukos Stock Up 1.1%

NYSE GKOS traded up $1.03 during trading on Tuesday, reaching $97.05. The company's stock had a trading volume of 1,111,096 shares, compared to its average volume of 699,671. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $5.55 billion, a PE ratio of -33.82 and a beta of 0.83. Glaukos Co. has a 1-year low of $77.10 and a 1-year high of $163.71. The business has a 50-day moving average price of $93.25 and a 200-day moving average price of $124.03.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.11. The business had revenue of $106.66 million during the quarter, compared to analyst estimates of $102.78 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. Glaukos's quarterly revenue was up 24.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.70) EPS. On average, research analysts forecast that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.